Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ACHV | 8-K | neutral | 3/10 | Achieve Life Sciences announced the appointment of Benjamin Halladay as CFO, effective October 5, 2026, replacing Mark O | Oct 1, 2026 |
| AKTX | 8-K | neutral | 3/10 | Akari Therapeutics amended its CEO's employment agreement, increasing annual base salary from $475,000 to $625,000 and t | Oct 1, 2026 |
| MNPR | 144 | neutral | 3/10 | Director Christopher Starr filed a Form 144 notice of intent to sell 16,800 shares of Monopar Therapeutics common stock, | Oct 1, 2026 |
| JAZZ | 144 | neutral | 2/10 | Bruce C. Cozadd, Chairman and former CEO of Jazz Pharmaceuticals, filed a Form 144 notice of intent to sell 6,000 shares | Oct 1, 2026 |
| SGMT | PRESS-RELEASE | bearish | 6/10 | Sagimet Biosciences closed a $115M underwritten offering of 8.75M shares of Series A common stock and pre-funded warrant | Oct 1, 2026 |
| SLBT | SC 13D/A | neutral | 3/10 | Ching-Dong Wang and SL Link Holding Ltd. filed an amendment to Schedule 13D, reporting beneficial ownership of 333,832,1 | Oct 1, 2026 |
| FBIO | 8-K | bullish | 5/10 | Fortress Biotech repaid the remaining $15.0 million in outstanding principal under its Oaktree senior secured credit fac | Oct 1, 2026 |
| RAPP | CLUSTER | neutral | 3/10 | Two insiders at Rapport Therapeutics sold a total of $270K in shares over a one-week window in late September 2026. The | Oct 1, 2026 |
| NBTX | 6-K | neutral | 2/10 | Nanobiotix appointed Arnd Christ as CFO effective October 1, 2026, replacing Bart Van Rhijn who stepped down after five | Oct 1, 2026 |
| UNCY | 3 | neutral | 2/10 | Meredith Manning filed a Form 3 initial statement of beneficial ownership with Unicycive Therapeutics, reporting no secu | Oct 1, 2026 |
| XERS | 144 | neutral | 3/10 | Beth Hecht, an officer of Xeris Biopharma Holdings, Inc., filed a Form 144 on October 1, 2026, indicating intent to sell | Oct 1, 2026 |
| ADRX | PRESS-RELEASE | bullish | 7/10 | ADARx Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 3,937,500 shares | Oct 1, 2026 |
| NBTX | PRESS-RELEASE | neutral | 2/10 | Nanobiotix announced the appointment of Arnd Christ as CFO, replacing Bart Van Rhijn. The filing is a routine executive | Oct 1, 2026 |
| MAZE | 144 | neutral | 2/10 | Jason V. Coloma, an officer of Maze Therapeutics, filed a Form 144 notice of intent to sell 34,501 shares of common stoc | Oct 1, 2026 |
| LTRN | 8-K | bearish | 7/10 | Lantern Pharma received a Nasdaq delisting notice on September 25, 2026, for failing to meet the $35 million minimum mar | Oct 1, 2026 |
| ADRX | SC 13G | neutral | 3/10 | BCLS Fund III Investments, LP (a Bain Capital Life Sciences entity) disclosed a 6.3% passive stake in ADARx Pharmaceutic | Oct 1, 2026 |
| CNBX | 8-K | bearish | 5/10 | CNBX Pharmaceuticals dismissed its auditor, Elkana Amitai CPA, and hired Vilki & Co., a firm based in Gujarat, India, ef | Oct 1, 2026 |
| QCLS | PRESS-RELEASE | neutral | 3/10 | Q/C Technologies announced a collaboration with Sandia National Laboratories' Center for Integrated Nanotechnologies (CI | Oct 1, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma (formerly Cybin Inc.) completed its legal name change to Helus Pharma Inc., effective October 1, 2026, foll | Oct 1, 2026 |
| SNY | 6-K | mixed | 5/10 | Sanofi and Regeneron announced an expansion of their antibody collaboration, adding four next-generation, long-acting im | Oct 1, 2026 |
| AZN | 6-K | neutral | 1/10 | AstraZeneca filed a 6-K reporting the admission of 9,828 new ordinary shares under its employee share schemes, increasin | Oct 1, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced first clinical data for ubamatamab (MUC16xCD3 bispecific) in low-grade serous ovarian cancer (LGSOC) | Oct 1, 2026 |
| AZN | 6-K | neutral | 1/10 | AstraZeneca filed a routine 6-K disclosing its total voting rights as of September 30, 2026. The filing confirms 1,551,0 | Oct 1, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced positive Phase 2 COURAGE trial results for trevogrumab (anti-myostatin) showing preservation of lean | Oct 1, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK plc filed a routine total voting rights notification under UK disclosure rules, reporting 4,045,430,485 voting right | Oct 1, 2026 |
| HCWB | DEF 14A | bearish | 5/10 | HCW Biologics is holding a special meeting on November 17, 2026 to seek stockholder approval for the issuance of up to 6 | Oct 1, 2026 |
| PYXS | 424B5 | bearish | 6/10 | Pyxis Oncology priced a $110.0 million underwritten public offering of 36,047,919 shares of common stock (and pre-funded | Oct 1, 2026 |
| GANX | PRESS-RELEASE | neutral | 4/10 | Gain Therapeutics presented Phase 1b open-label extension data for rexaceract (GT-02287) at the MDS Congress, showing MD | Oct 1, 2026 |
| XENE | CLUSTER | bullish | 6/10 | Xenon Pharmaceuticals' CEO and CFO made open-market purchases totaling $1.68M on the same day, with the CEO alone buying | Oct 1, 2026 |
| ERNA | PRESS-RELEASE | neutral | 4/10 | Ernexa Therapeutics announced the appointment of Dr. Robert J. Spiegel to its Board of Directors and provided a pipeline | Oct 1, 2026 |